Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 3 |
| INN | Abciximab |
| Status | Approved |
| Drug code(s) | 7E 3 |
| Brand name | Reopro |
| mAb sequence source | mAb chimeric |
| General Molecular Category | Naked monospecific |
| Format, general category | Fragment |
| Format details | Fab |
| Isotype (Fc) | None |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | GP IIb/IIIa receptor |
| Indications of clinical studies | Prevention of blood clots |
| Primary therapeutic area | Cardiovascular / hemostasis disorders |
| Most advanced stage of development (global) | Approved EU, US |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | July 02, 1987 |
| Start of Phase 2 | November 15, 1989 |
| Start of Phase 3 | November 26, 1991 |
| Date BLA/NDA submitted to FDA | December 16, 1993 |
| Year of first approval (global) | 1994 |
| Date of first US approval | December 22, 1994 |
| INN, US product name | Abciximab |
| US or EU approved indications | Acute Coronary Syndrome, Percutaneous Coronary Interventions for Stable Angina |
| Company | Centocor |
| Licensee/Partner | Tanabe Seiyaku |
| Comments about company or candidate | None |
| Full address of company | 800-850 Ridgeview Drive HORSHAM PA 19044 UNITED STATES North America United States of America https://www.orpha.net/en/institutions/legal-entity/82182 |
None
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |